.
MergerLinks Header Logo

New Deal


Announced

Completed

Getinge completed the acquisition of High Purity New England for $290m.

Financials

Edit Data
Transaction Value£240m
Consideration TypeContingent Deferred Consideration, Cash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Acquisition

United States

biotechnology company

Single Bidder

Biotechnology

Cross Border

Majority

Private

Friendly

Completed

Synopsis

Edit

Getinge, a global medical technology company, completed the acquisition of High Purity New England, a provider of single-use solutions for bioprocessing applications, for $290m. "This acquisition is another step in Getinge Life Science strategic journey to further expand our presence in the biopharma segment. High Purity New England has in recent years successfully supplied the industry with dedicated single use assemblies. We are delighted to join forces with HPNE providing our customers with comprehensive and innovative solutions for bioprocessing applications," Eric Honroth, Getinge President Life Science.

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US